Coming Soon

Fidelis Pharmaceuticals is committed to supplying the lab animal professional with pharmaceutical grade products that meet a high standard for quality. We will provide dates of Ethiqa XR availability as soon as possible, and thank you for your patience.

Ready for Distribution in Early 2020

Easy to order

We are excited to announce that MWI Animal Health will distribute NEW Ethiqa XR™ beginning in early 2020.

MWI Animal Health is focused on providing broad product access to animal health providers as well as helping clinical teams address the daily challenges of our industry. From inventory management to financing solutions, MWI’s innovative services and best-in-class distribution network are backed by a salesforce known for quality and expertise.

If you would like to set up an account with MWI, visit www.mwiah.com > Account Access (on top right, drop down menu to Open Account) > Scroll down to Government, university or research facility account and click Create Account. If you have questions or for more information about MWI email LabAnimal@mwiah.com.

This formulation contains buprenorphine, a high-concentration (1.3 mg/mL) opioid agonist and Schedule III controlled substance with an abuse potential similar to other Schedule III opioids. The high concentration may be a particular target for human abuse. Buprenorphine has opioid properties that in humans may lead to dependence of the morphine type. Abuse of buprenorphine may lead to low or moderate physical dependence or high psychological dependence. The risk of abuse by humans should be considered when storing, administering, and disposing. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (suicidal depression). Because of human safety risks, this drug should be used only with veterinary supervision.

Do not dispense this formulation.

Life-Threatening Respiratory Depression

The concentration of buprenorphine is 1.3 mg/mL. Respiratory depression, including fatal cases, may occur with abuse of this formulation. There are additive CNS depressant effects when used with alcohol, other opioids, or illicit drugs that cause central nervous system depression. Because of the potential for adverse reactions associated with accidental injection, this formulation should only be administered by a veterinarian or laboratory staff trained in the handling of potent opioids.